Cytotoxic T-lymphocyte-associated Protein 4 Archives

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

March 10, 2022

The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma (HCC) setting. No hypothesis

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line Advanced Melanoma

March 10, 2022

By Support_Clique

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of

Study Keyword: Cytotoxic T-lymphocyte-associated Protein 4

Study Keyword: Cytotoxic T-lymphocyte-associated Protein 4

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line Advanced Melanoma